Jiangsu Vcare Pharmatech
PrivateLast Round
Series C
Jan 2, 2024
Total Funding Raised
$107.6M
Company Overview
Jiangsu Vcare Pharmatech Co., Ltd., established in 2010, is a high-tech biopharmaceutical company based in Nanjing, China. The company focuses on addressing unmet clinical needs through drug development and advanced therapies. It operates as a group-style enterprise with two main business segments: innovative drug R&D and comprehensive pharmaceutical industry chain services (CRO/CDMO). Its drug pipeline includes several Class I innovative drugs in clinical development, such as Vicagrel (an oral anti-thrombotic agent), VC004 (an oral anti-tumor therapy), and VC005 (an immunomodulatory and anti-inflammatory agent). In 2021, its CRO/CDMO business was spun off into a wholly-owned subsidiary, Nanjing Vcare Pharmatech Co., Ltd., to provide a one-stop service platform. The company has raised over RMB 1 billion through multiple funding rounds.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Clinical Trials, Pharma Supply Chain, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jiangsu Vcare Pharmatech Comps
Public and private peers based on sector, stage, and business model.
Jiangsu Vcare Pharmatech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 2, 2024 | ||||
| Series B | Dec 27, 2022 | ||||
| Series A Extension | May 6, 2022 | ||||
| Series A | Jul 29, 2021 |
Jiangsu Vcare Pharmatech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hongcheng Capital | Series B |
| DYEE Capital | Series C |
| 南京市创新投资集团有限责任公司 | Series C, Series A |
| China Life Private Equity Investment | Series C |
| Yangtze River Industry Group | Series A Extension, Series B |
Jiangsu Vcare Pharmatech Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Jiangsu Vcare Pharmatech's valuation, stock price, and market status.
